ArticleAntimicrobial agents and chemotherapy2022
Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021.
Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of doxycycline for severe Mycoplasma pneumoniae pneumonia in pediatric patients.Clinical and experimental medicine · 2025Pooled it
- Association between point mutations of macrolide-resistantFrontiers in pharmacology · 2025Pooled it
- Reporting macrolide-resistantJournal of clinical microbiology · 2026Review
- Genomic Surveillance Reveals Emergence and Spread of Macrolide-Resistant Mycoplasma pneumoniae in Australia During the 2023-2024 Epidemic.The Journal of infectious diseases · 2026Article
- Beyond Ribosomal Mutations: Identification ofMicroorganisms · 2026Article
- Genome-wide association studies builds a predictive model and reveals novel resistance features for macrolide-resistant Bordetella pertussis.The Journal of antimicrobial chemotherapy · 2026Article
- Economic burden ofFrontiers in public health · 2026Article
- Suspected Macrolide-RefractoryCase reports in infectious diseases · 2026Article
- Protective immunity induced by a novel P1 adhesin C-terminal anchored mRNA vaccine againstMicrobiology spectrum · 2025Article
- Recent Macrolide Resistance Pattern of Mycoplasma Pneumonia in the World: A Systematic Review and Meta-Analysis.Iranian journal of public health · 2025Review
- Macrolide resistance inFrontiers in cellular and infection microbiology · 2025Article
- The epidemic characteristics ofMicrobiology spectrum · 2024Article
- Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.World journal of pediatrics : WJP · 2024Review
- miRNA, lncRNA and circRNA: targeted molecules with therapeutic promises in Mycoplasma pneumoniae infection.Archives of microbiology · 2023Review
- Clinical characteristics of community-acquired pneumonia in children caused by mycoplasma pneumoniae with or without myocardial damage: A single-center retrospective study.World journal of clinical pediatrics · 2023Article
- Clinical Value of Metagenomics Next-Generation Sequencing in Antibiotic Resistance of a Patient with Severe RefractoryInfection and drug resistance · 2023Article
- Phenotypic and genotypic antimicrobial susceptibility patterns of the emerging human respiratory pathogen Mycoplasma amphoriforme isolated from the UK and Denmark.The Journal of antimicrobial chemotherapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epidemiology of macrolide resistance in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.